Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.72 |
| ▸ | TUBB | P07437 | 3/20 | 0.72 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.72 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.72 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.72 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.72 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.72 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.72 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.72 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.72 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.72 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.72 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.72 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.72 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.72 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6627733 | 0.95 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4709615 | 0.90 | PDE4D (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8726318 | 0.84 | GABRA1 (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4708083 | 0.84 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5038191 | 0.83 | TUBB4A (0.58) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5349947 | 0.83 | GABRA1 (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1365846 | 0.80 | GABRA1 (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Ro-052921 SCHEMBL29979594 | 0.79 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Ro-052921 SCHEMBL1365706 | 0.79 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5486155 | 0.79 | GABRA1 (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | claimed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7238685-B2 | Benzo-fused heterocycles as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-03 | — | — | US | disclosed |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | ACTELION PHARMACEUTICALS LTD. | 2005-06-09 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | EDNRA, EDNRB, ECE1 | TUBB4A 4806/4885TUBB 4734/4885TUBA3C 4622/4885 |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | TUBB4A 2409/4885TUBB 1900/4885TUBA3C 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.